bpc-157 fda approved status This is the first vote from the FDA's Pharmacy Compounding Advisory Committee on one of 7 peptides up for consideration. While the committee advises through these votes, ultimately the will make bpc 157 fda classification Survey:

| Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from a protective protein found in gastric juice, attracting growing interest in regenerative medicine for tendon and ligament repair

Separately, RegeneRx's ophthalmic formulation RGN-259 completed Phase 3 trials (ARISE-1 and ARISE-2) for dry eye with mixed results

Some peptide therapies discussed on this page may be prepared by licensed compounding pharmacies when prescribed by a qualified healthcare provider

The single human dataset for musculoskeletal use is a retrospective chart review of sixteen knee-pain patients who paid for intra-articular injections, with subjective improvement reported in fourteen and no control, no blinded assessment, and no objective imaging endpoint